Asymmetric Dimethylarginine and Reactive Oxygen Species: Unwelcome Twin Visitors to the Cardiovascular and Kidney Disease Tables
Plasma levels of asymmetric dimethylarginine or markers of reactive oxygen species are increased in subjects with risk factors for cardiovascular disease or chronic kidney disease. We tested the hypothesis that reactive oxygen species generate cellular asymmetric dimethylarginine that together cause...
Saved in:
Published in | Hypertension (Dallas, Tex. 1979) Vol. 59; no. 2 Suppl 1; pp. 375 - 381 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
Hagerstown, MD
American Heart Association, Inc
01.02.2012
Lippincott Williams & Wilkins |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Plasma levels of asymmetric dimethylarginine or markers of reactive oxygen species are increased in subjects with risk factors for cardiovascular disease or chronic kidney disease. We tested the hypothesis that reactive oxygen species generate cellular asymmetric dimethylarginine that together cause endothelial dysfunction that underlies the risk of subsequent disease. Rat preglomerular vascular smooth muscle cells transfected with p22 had increased NADPH oxidase activity, enhanced activity and expression of protein arginine methyltransferase, and reduced activity and protein expression of dimethylarginine dimethylaminotransferase and of cationic amino acid transferase 1 resulting in increased cellular levels of asymmetric dimethylarginine. Rats infused with angiotensin II had oxidative stress. The endothelial function of their mesenteric arterioles was changed from vasodilatation to vasoconstriction, accompanied by increased vascular asymmetric dimethylarginine. All of these changes were prevented by Tempol. In vivo silencing of dimethylarginine dimethylaminotransferase 1 increased plasma levels of asymmetric dimethylarginine, whereas silencing of dimethylarginine dimethylaminotransferase 2 impaired endothelial function. We suggest that initiation factors, such as angiotensin II, expressed in blood vessels or tissues of subjects with cardiovascular and kidney disease risk factors generate reactive oxygen species from NADPH oxidase that enhances cellular asymmetric dimethylarginine in an amplification loop. This leads to adverse changes in vascular and organ functions, as a consequence of reduced tissue levels of NO and increased reactive oxygen species. Thus, we conclude that reactive oxygen species and asymmetric dimethylarginine form a tightly coupled amplification system that translates cardiovascular/kidney risk into overt disease. |
---|---|
AbstractList | Plasma levels of asymmetric dimethylarginine or markers of reactive oxygen species are increased in subjects with risk factors for cardiovascular disease or chronic kidney disease. We tested the hypothesis that reactive oxygen species generate cellular asymmetric dimethylarginine that together cause endothelial dysfunction that underlies the risk of subsequent disease. Rat preglomerular vascular smooth muscle cells transfected with p22
phox
had increased NADPH oxidase activity, enhanced activity and expression of protein arginine methyltransferase, and reduced activity and protein expression of dimethylarginine dimethylaminotransferase and of cationic amino acid transferase 1 resulting in increased cellular levels of asymmetric dimethylarginine. Rats infused with angiotensin II had oxidative stress. The endothelial function of their mesenteric arterioles was changed from vasodilatation to vasoconstriction, accompanied by increased vascular asymmetric dimethylarginine. All of these changes were prevented by Tempol. In vivo silencing of dimethylarginine dimethylaminotransferase 1 increased plasma levels of asymmetric dimethylarginine, whereas silencing of dimethylarginine dimethylaminotransferase 2 impaired endothelial function. We suggest that initiation factors, such as angiotensin II, expressed in blood vessels or tissues of subjects with cardiovascular and kidney disease risk factors generate reactive oxygen species from NADPH oxidase that enhances cellular asymmetric dimethylarginine in an amplification loop. This leads to adverse changes in vascular and organ functions, as a consequence of reduced tissue levels of NO and increased reactive oxygen species. Thus, we conclude that reactive oxygen species and asymmetric dimethylarginine form a tightly coupled amplification system that translates cardiovascular/kidney risk into overt disease. Plasma levels of asymmetric dimethylarginine or markers of reactive oxygen species are increased in subjects with risk factors for cardiovascular disease or chronic kidney disease. We tested the hypothesis that reactive oxygen species generate cellular asymmetric dimethylarginine that together cause endothelial dysfunction that underlies the risk of subsequent disease. Rat preglomerular vascular smooth muscle cells transfected with p22(phox) had increased NADPH oxidase activity, enhanced activity and expression of protein arginine methyltransferase, and reduced activity and protein expression of dimethylarginine dimethylaminotransferase and of cationic amino acid transferase 1 resulting in increased cellular levels of asymmetric dimethylarginine. Rats infused with angiotensin II had oxidative stress. The endothelial function of their mesenteric arterioles was changed from vasodilatation to vasoconstriction, accompanied by increased vascular asymmetric dimethylarginine. All of these changes were prevented by Tempol. In vivo silencing of dimethylarginine dimethylaminotransferase 1 increased plasma levels of asymmetric dimethylarginine, whereas silencing of dimethylarginine dimethylaminotransferase 2 impaired endothelial function. We suggest that initiation factors, such as angiotensin II, expressed in blood vessels or tissues of subjects with cardiovascular and kidney disease risk factors generate reactive oxygen species from NADPH oxidase that enhances cellular asymmetric dimethylarginine in an amplification loop. This leads to adverse changes in vascular and organ functions, as a consequence of reduced tissue levels of NO and increased reactive oxygen species. Thus, we conclude that reactive oxygen species and asymmetric dimethylarginine form a tightly coupled amplification system that translates cardiovascular/kidney risk into overt disease.Plasma levels of asymmetric dimethylarginine or markers of reactive oxygen species are increased in subjects with risk factors for cardiovascular disease or chronic kidney disease. We tested the hypothesis that reactive oxygen species generate cellular asymmetric dimethylarginine that together cause endothelial dysfunction that underlies the risk of subsequent disease. Rat preglomerular vascular smooth muscle cells transfected with p22(phox) had increased NADPH oxidase activity, enhanced activity and expression of protein arginine methyltransferase, and reduced activity and protein expression of dimethylarginine dimethylaminotransferase and of cationic amino acid transferase 1 resulting in increased cellular levels of asymmetric dimethylarginine. Rats infused with angiotensin II had oxidative stress. The endothelial function of their mesenteric arterioles was changed from vasodilatation to vasoconstriction, accompanied by increased vascular asymmetric dimethylarginine. All of these changes were prevented by Tempol. In vivo silencing of dimethylarginine dimethylaminotransferase 1 increased plasma levels of asymmetric dimethylarginine, whereas silencing of dimethylarginine dimethylaminotransferase 2 impaired endothelial function. We suggest that initiation factors, such as angiotensin II, expressed in blood vessels or tissues of subjects with cardiovascular and kidney disease risk factors generate reactive oxygen species from NADPH oxidase that enhances cellular asymmetric dimethylarginine in an amplification loop. This leads to adverse changes in vascular and organ functions, as a consequence of reduced tissue levels of NO and increased reactive oxygen species. Thus, we conclude that reactive oxygen species and asymmetric dimethylarginine form a tightly coupled amplification system that translates cardiovascular/kidney risk into overt disease. Plasma levels of asymmetric dimethylarginine or markers of reactive oxygen species are increased in subjects with risk factors for cardiovascular disease or chronic kidney disease. We tested the hypothesis that reactive oxygen species generate cellular asymmetric dimethylarginine that together cause endothelial dysfunction that underlies the risk of subsequent disease. Rat preglomerular vascular smooth muscle cells transfected with p22(phox) had increased NADPH oxidase activity, enhanced activity and expression of protein arginine methyltransferase, and reduced activity and protein expression of dimethylarginine dimethylaminotransferase and of cationic amino acid transferase 1 resulting in increased cellular levels of asymmetric dimethylarginine. Rats infused with angiotensin II had oxidative stress. The endothelial function of their mesenteric arterioles was changed from vasodilatation to vasoconstriction, accompanied by increased vascular asymmetric dimethylarginine. All of these changes were prevented by Tempol. In vivo silencing of dimethylarginine dimethylaminotransferase 1 increased plasma levels of asymmetric dimethylarginine, whereas silencing of dimethylarginine dimethylaminotransferase 2 impaired endothelial function. We suggest that initiation factors, such as angiotensin II, expressed in blood vessels or tissues of subjects with cardiovascular and kidney disease risk factors generate reactive oxygen species from NADPH oxidase that enhances cellular asymmetric dimethylarginine in an amplification loop. This leads to adverse changes in vascular and organ functions, as a consequence of reduced tissue levels of NO and increased reactive oxygen species. Thus, we conclude that reactive oxygen species and asymmetric dimethylarginine form a tightly coupled amplification system that translates cardiovascular/kidney risk into overt disease. Plasma levels of asymmetric dimethylarginine or markers of reactive oxygen species are increased in subjects with risk factors for cardiovascular disease or chronic kidney disease. We tested the hypothesis that reactive oxygen species generate cellular asymmetric dimethylarginine that together cause endothelial dysfunction that underlies the risk of subsequent disease. Rat preglomerular vascular smooth muscle cells transfected with p22 had increased NADPH oxidase activity, enhanced activity and expression of protein arginine methyltransferase, and reduced activity and protein expression of dimethylarginine dimethylaminotransferase and of cationic amino acid transferase 1 resulting in increased cellular levels of asymmetric dimethylarginine. Rats infused with angiotensin II had oxidative stress. The endothelial function of their mesenteric arterioles was changed from vasodilatation to vasoconstriction, accompanied by increased vascular asymmetric dimethylarginine. All of these changes were prevented by Tempol. In vivo silencing of dimethylarginine dimethylaminotransferase 1 increased plasma levels of asymmetric dimethylarginine, whereas silencing of dimethylarginine dimethylaminotransferase 2 impaired endothelial function. We suggest that initiation factors, such as angiotensin II, expressed in blood vessels or tissues of subjects with cardiovascular and kidney disease risk factors generate reactive oxygen species from NADPH oxidase that enhances cellular asymmetric dimethylarginine in an amplification loop. This leads to adverse changes in vascular and organ functions, as a consequence of reduced tissue levels of NO and increased reactive oxygen species. Thus, we conclude that reactive oxygen species and asymmetric dimethylarginine form a tightly coupled amplification system that translates cardiovascular/kidney risk into overt disease. |
Author | Wilcox, Christopher S. |
AuthorAffiliation | From the Division of Nephrology and Hypertension and Hypertension, Kidney, and Vascular Research Center, Georgetown University, Washington, DC |
AuthorAffiliation_xml | – name: From the Division of Nephrology and Hypertension and Hypertension, Kidney, and Vascular Research Center, Georgetown University, Washington, DC |
Author_xml | – sequence: 1 givenname: Christopher surname: Wilcox middlename: S. fullname: Wilcox, Christopher S. organization: From the Division of Nephrology and Hypertension and Hypertension, Kidney, and Vascular Research Center, Georgetown University, Washington, DC |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25493495$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22215715$$D View this record in MEDLINE/PubMed |
BookMark | eNqNks1uEzEUhS1URNPCKyALCbGa4t_JuCuiEEhF1aA2RbAaOZ7rxuDxBHvSkB2PjkMCSF3hja2j75wr-_gEHYUuAEIvKDmjtKSvp18-Tq7nk6ubi9nVaDrKIj2j1ZBT8ggNqGSiELLkR2hAqBKFovTzMTpJ6SshVAgxfIKOGWNUDqkcoJ-jtG1b6KMz-K3Lh-XW63jngguAdWjwNWjTu3vAsx_bOwj4ZgXGQTrHt2ED3nQt4PnGBfzJJdd3MeG-w_0S8FjHxnX3Opl1Dvwd9cE1AbZ5TAKdsk0vPKSn6LHVPsGzw36Kbt9N5uNpcTl7fzEeXRaGK84L1ljDlBaMUlFZ0TSkspJTKa2x1lSSgGCNMQupF2VlbSktU6VcNFbJqizB8FP0ap-7it33NaS-bl0y4L0O0K1TrWhFuFRKZPL5gVwvWmjqVXStjtv6z6Nl4OUByLfT3kYdjEv_OCkUF2rHne85E7uUIti_CCX1rsn6QZNZpPW-yWx-88BsXK9714U-auf_L0LsIzad7yGmb369gVgvQft-WZO8BCurghHKCMufo9hJnP8CLXe4_Q |
CODEN | HPRTDN |
CitedBy_id | crossref_primary_10_1016_j_jacadv_2025_101590 crossref_primary_10_1093_ndt_gfv380 crossref_primary_10_1093_ajh_hpu129 crossref_primary_10_1161_CIRCRESAHA_121_318082 crossref_primary_10_1042_CS20210566 crossref_primary_10_1093_ndt_gfy174 crossref_primary_10_1016_j_physbeh_2020_113295 crossref_primary_10_1038_s41440_018_0122_5 crossref_primary_10_1093_ndt_gfu219 crossref_primary_10_3389_fphys_2014_00292 crossref_primary_10_1016_j_niox_2013_02_080 crossref_primary_10_1186_s12882_015_0162_x crossref_primary_10_1007_s00726_015_2096_9 crossref_primary_10_1074_jbc_M115_651380 crossref_primary_10_1016_j_ejphar_2012_09_019 crossref_primary_10_1016_j_niox_2017_04_002 crossref_primary_10_1097_PEC_0000000000001339 crossref_primary_10_1007_s12668_024_01617_4 crossref_primary_10_2478_jomb_2018_0025 crossref_primary_10_3389_fphys_2014_00531 crossref_primary_10_3390_jcm9093026 crossref_primary_10_1016_j_bbrep_2017_04_017 crossref_primary_10_1152_ajprenal_00045_2012 crossref_primary_10_3109_10715762_2015_1006215 crossref_primary_10_1016_j_transproceed_2014_12_014 crossref_primary_10_1016_j_trsl_2014_07_006 crossref_primary_10_1016_j_bas_2023_101745 crossref_primary_10_3389_fimmu_2022_918241 crossref_primary_10_1016_j_jstrokecerebrovasdis_2020_105376 crossref_primary_10_1016_j_bbrc_2015_08_043 crossref_primary_10_1016_j_biopha_2025_117958 crossref_primary_10_1016_j_biopha_2018_07_096 crossref_primary_10_1161_CIRCULATIONAHA_115_017923 crossref_primary_10_3390_metabo13020266 crossref_primary_10_15171_jarcm_2015_037 crossref_primary_10_1089_ars_2020_8184 crossref_primary_10_1152_ajpregu_00122_2017 crossref_primary_10_1161_CIRCRESAHA_116_302855 crossref_primary_10_1016_j_pharmthera_2013_07_004 crossref_primary_10_1016_j_semnephrol_2014_08_004 crossref_primary_10_1038_s41397_019_0082_4 crossref_primary_10_1093_ehjci_jet120 crossref_primary_10_1007_s00726_014_1825_9 crossref_primary_10_3390_jcm9082359 crossref_primary_10_3889_oamjms_2021_6572 crossref_primary_10_1152_ajprenal_00560_2017 crossref_primary_10_3390_ijms18040841 crossref_primary_10_1161_HYPERTENSIONAHA_114_04760 crossref_primary_10_3390_diagnostics13162709 crossref_primary_10_3390_antiox11050845 crossref_primary_10_3390_ijms14048062 crossref_primary_10_1111_bph_13380 crossref_primary_10_1371_journal_pone_0120287 crossref_primary_10_1042_CS20120074 crossref_primary_10_1111_apha_12646 crossref_primary_10_1016_j_cca_2014_11_002 crossref_primary_10_1177_0004563218822655 crossref_primary_10_3390_ijms17122020 crossref_primary_10_1007_s00394_017_1548_2 crossref_primary_10_3390_ijms140917553 |
Cites_doi | 10.1177/1358836X0501000106 10.1016/j.vph.2005.09.005 10.1161/01.CIR.99.24.3092 10.1177/1358836X0501000104 10.1093/eurheartj/ehp061 10.1021/bi702377a 10.1093/ajh/3.3.242 10.1016/j.pharmthera.2010.01.003 10.1161/hypertensionaha.111.170472 10.1038/sj.ki.5001983 10.1152/ajpheart.00134.2002 10.2337/diacare.27.3.765 10.1161/circresaha.107.158915 10.1172/JCI200314172 10.1093/cvr/cvq366 10.1152/ajpheart.00998.2007 10.1016/0006-291X(87)90929-6 10.1042/CS20050307 10.1161/atvbaha.110.222638 10.1161/01.HYP.38.3.655 10.1124/pr.108.000240 10.1016/S0091-679X(08)60010-2 10.1016/j.freeradbiomed.2008.08.013 10.1016/0003-9861(87)90060-9 10.1161/01.cir.0000093661.90582.c4 10.1016/j.jacc.2008.04.019 10.1002/cbic.200500527 10.1172/JCI118623 10.1056/NEJMoa013591 10.1038/ncpneph0143 10.1006/niox.1996.0106 10.1161/01.hyp.0000156746.25300.1c 10.1161/01.atv.0000128897.54893.26 10.1152/ajprenal.00423.2003 10.1016/j.freeradbiomed.2007.06.019 10.1152/ajpheart.1986.250.5.H822 10.2337/db06-1772 10.1161/circresaha.107.156901 10.1161/01.RES.80.1.45 10.1097/01.ASN.0000090747.59919.D2 10.1007/s11906-011-0187-x 10.1093/ndt/17.11.1999 10.1097/00005344-199204002-00018 10.1248/bpb.28.641 10.1016/S0165-6147(03)00233-5 10.1172/JCI118935 10.1161/01.CIR.98.18.1842 10.1016/j.freeradbiomed.2011.06.011 10.1111/j.1523-1755.2005.00392.x 10.1152/ajpheart.01103.2007 10.1159/000103284 10.1053/j.ajkd.2007.09.020 10.1161/ATVBAHA.108.181610 10.1074/jbc.M109.037036 10.1046/j.1365-2362.2003.01150.x 10.1161/01.hyp.0000259669.40991.1e 10.1089/ars.2006.8.1597 10.1161/hypertensionaha.110.157115 10.1016/j.freeradbiomed.2009.07.006 10.1016/j.phrs.2009.08.002 10.1016/S0895-7061(02)02278-1 10.1016/S0021-9258(18)62716-4 10.1161/hypertensionaha.109.135426 10.1161/01.RES.87.2.99 10.1046/j.1523-1755.2002.00437.x 10.1038/hr.2010.201 10.1016/S0140-6736(01)07217-8 10.1161/01.res.0000129578.76799.75 10.1161/01.hyp.0000200023.02195.73 10.1038/sj.ki.5000067 10.1152/ajpheart.00626.2004 10.1093/ndt/gfg452 10.1111/j.1476-5381.2009.00259.x 10.1161/hypertensionaha.110.152959 10.1007/s10157-008-0034-9 10.1161/01.RES.0000020404.01971.2F 10.1161/01.hyp.0000158262.11935.d0 10.1161/01.hyp.0000154365.30593.d3 10.1111/j.1523-1755.2000.00380.x 10.1161/01.hyp.0000052945.84627.8f 10.1152/ajpregu.90506.2008 10.1016/S0021-9258(18)81786-0 10.1016/j.bbrc.2004.01.120 10.1038/sj.ki.5000417 10.1161/hypertensionaha.109.142422 10.1152/ajpregu.90875.2008 10.1152/ajpregu.00250.2005 |
ContentType | Journal Article |
Copyright | 2012 American Heart Association, Inc. 2015 INIST-CNRS |
Copyright_xml | – notice: 2012 American Heart Association, Inc. – notice: 2015 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1161/HYPERTENSIONAHA.111.187310 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1524-4563 |
EndPage | 381 |
ExternalDocumentID | 22215715 25493495 10_1161_HYPERTENSIONAHA_111_187310 00004268-201202001-00003 |
Genre | Review Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NIDDK NIH HHS grantid: R01 DK036079 – fundername: NIDDK NIH HHS grantid: DK-049870 – fundername: NHLBI NIH HHS grantid: P01 HL068686 – fundername: NIAID NIH HHS grantid: AI-034994 – fundername: NIDDK NIH HHS grantid: R01 DK049870 – fundername: NIAID NIH HHS grantid: AI-087714 – fundername: NIDDK NIH HHS grantid: DK-036079 – fundername: NIAID NIH HHS grantid: U01 AI034994 – fundername: NHLBI NIH HHS grantid: HL-068686 – fundername: NIDDK NIH HHS grantid: R37 DK036079 |
GroupedDBID | --- .-D .3C .55 .GJ .XZ .Z2 01R 0R~ 18M 1J1 2WC 3O- 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 71W 77Y 7O~ AAAAV AAAXR AAFWJ AAGIX AAHPQ AAIQE AAJCS AAMOA AAMTA AAQKA AARTV AASCR AASOK AAXQO AAYEP ABASU ABBUW ABDIG ABJNI ABOCM ABPXF ABQRW ABVCZ ABXVJ ABXYN ABZAD ABZZY ACCJW ACDDN ACEWG ACGFO ACGFS ACILI ACLDA ACWDW ACWRI ACXJB ACXNZ ACZKN ADBBV ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEBDS AEETU AENEX AFBFQ AFDTB AFEXH AFFNX AFNMH AFUWQ AGINI AHMBA AHOMT AHQNM AHQVU AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC BAWUL BCGUY BOYCO BQLVK BS7 C1A C45 CS3 DIK DIWNM DUNZO E.X E3Z EBS EEVPB EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG FL- FW0 GNXGY GQDEL GX1 H0~ H13 HLJTE HZ~ IKREB IKYAY IN~ IPNFZ JF9 JG8 JK3 JK8 K-A K-F K8S KD2 KMI KQ8 L-C L7B N4W N9A N~7 N~B N~M O9- OAG OAH OB3 OCUKA ODA ODMTH OGROG OHYEH OK1 OL1 OLG OLH OLU OLV OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OWBYB OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P PQQKQ R58 RAH RIG RLZ S4R S4S T8P TEORI TR2 TSPGW V2I VVN W3M W8F WH7 WOQ WOW X3V X3W X7M XXN XYM YFH YHZ YOC YYM YYP ZFV ZGI ZZMQN AAYXX ADGHP CITATION IQODW OZ- CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c3933-2dfc29a421148f4dd08f53155fcffc850e42dccb5ab68ff65f2965bdf95866ec3 |
ISSN | 0194-911X 1524-4563 |
IngestDate | Mon Jul 21 09:27:16 EDT 2025 Sat May 31 02:08:10 EDT 2025 Mon Jul 21 09:13:58 EDT 2025 Thu Apr 24 22:55:08 EDT 2025 Tue Jul 01 04:30:53 EDT 2025 Fri May 16 03:51:30 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 Suppl 1 |
Keywords | Hypertension NADPH Kidney disease endothelial function NO Oxygen Urinary system disease Enzyme Peptide hormone Oxidase Cardiovascular disease Twin Octapeptide NADPH oxidase Oxidoreductases Angiotensin II |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3933-2dfc29a421148f4dd08f53155fcffc850e42dccb5ab68ff65f2965bdf95866ec3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
PMID | 22215715 |
PQID | 918035994 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_918035994 pubmed_primary_22215715 pascalfrancis_primary_25493495 crossref_primary_10_1161_HYPERTENSIONAHA_111_187310 crossref_citationtrail_10_1161_HYPERTENSIONAHA_111_187310 wolterskluwer_health_00004268-201202001-00003 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2012-February |
PublicationDateYYYYMMDD | 2012-02-01 |
PublicationDate_xml | – month: 02 year: 2012 text: 2012-February |
PublicationDecade | 2010 |
PublicationPlace | Hagerstown, MD |
PublicationPlace_xml | – name: Hagerstown, MD – name: United States |
PublicationTitle | Hypertension (Dallas, Tex. 1979) |
PublicationTitleAlternate | Hypertension |
PublicationYear | 2012 |
Publisher | American Heart Association, Inc Lippincott Williams & Wilkins |
Publisher_xml | – name: American Heart Association, Inc – name: Lippincott Williams & Wilkins |
References | e_1_3_4_3_2 e_1_3_4_61_2 e_1_3_4_82_2 e_1_3_4_9_2 e_1_3_4_63_2 e_1_3_4_84_2 e_1_3_4_7_2 e_1_3_4_40_2 e_1_3_4_5_2 e_1_3_4_80_2 e_1_3_4_23_2 e_1_3_4_44_2 e_1_3_4_69_2 e_1_3_4_21_2 e_1_3_4_42_2 e_1_3_4_27_2 e_1_3_4_48_2 e_1_3_4_65_2 e_1_3_4_25_2 e_1_3_4_46_2 e_1_3_4_67_2 e_1_3_4_88_2 e_1_3_4_29_2 e_1_3_4_72_2 e_1_3_4_74_2 e_1_3_4_30_2 e_1_3_4_51_2 e_1_3_4_70_2 e_1_3_4_11_2 e_1_3_4_34_2 e_1_3_4_57_2 e_1_3_4_55_2 e_1_3_4_32_2 e_1_3_4_59_2 e_1_3_4_53_2 e_1_3_4_15_2 e_1_3_4_38_2 e_1_3_4_76_2 e_1_3_4_13_2 e_1_3_4_36_2 e_1_3_4_78_2 e_1_3_4_19_2 e_1_3_4_17_2 e_1_3_4_2_2 e_1_3_4_60_2 e_1_3_4_83_2 e_1_3_4_62_2 e_1_3_4_85_2 e_1_3_4_8_2 e_1_3_4_41_2 e_1_3_4_6_2 e_1_3_4_81_2 e_1_3_4_4_2 e_1_3_4_22_2 e_1_3_4_45_2 e_1_3_4_68_2 e_1_3_4_20_2 e_1_3_4_43_2 e_1_3_4_26_2 e_1_3_4_49_2 e_1_3_4_64_2 e_1_3_4_24_2 e_1_3_4_47_2 e_1_3_4_66_2 e_1_3_4_89_2 e_1_3_4_28_2 e_1_3_4_71_2 e_1_3_4_73_2 e_1_3_4_52_2 e_1_3_4_90_2 e_1_3_4_50_2 e_1_3_4_79_2 e_1_3_4_12_2 e_1_3_4_33_2 e_1_3_4_58_2 e_1_3_4_54_2 Wilcox CS (e_1_3_4_86_2) 1990; 38 e_1_3_4_10_2 e_1_3_4_31_2 e_1_3_4_75_2 e_1_3_4_16_2 e_1_3_4_37_2 e_1_3_4_77_2 e_1_3_4_14_2 e_1_3_4_35_2 e_1_3_4_56_2 e_1_3_4_18_2 e_1_3_4_39_2 Wilcox CS (e_1_3_4_87_2) 1993; 6 |
References_xml | – ident: e_1_3_4_18_2 doi: 10.1177/1358836X0501000106 – ident: e_1_3_4_49_2 doi: 10.1016/j.vph.2005.09.005 – ident: e_1_3_4_62_2 doi: 10.1161/01.CIR.99.24.3092 – ident: e_1_3_4_17_2 doi: 10.1177/1358836X0501000104 – ident: e_1_3_4_71_2 doi: 10.1093/eurheartj/ehp061 – ident: e_1_3_4_58_2 doi: 10.1021/bi702377a – ident: e_1_3_4_85_2 doi: 10.1093/ajh/3.3.242 – volume: 6 start-page: 124 year: 1993 ident: e_1_3_4_87_2 article-title: Vasoconstrictor prostaglandins in angiotensin-dependent and renovascular hypertension publication-title: J Nephrol – ident: e_1_3_4_27_2 doi: 10.1016/j.pharmthera.2010.01.003 – volume: 38 start-page: S81 year: 1990 ident: e_1_3_4_86_2 article-title: Angiotensin II and thromboxane in the regulation of blood pressure and renal function publication-title: Kidney Int – ident: e_1_3_4_23_2 doi: 10.1161/hypertensionaha.111.170472 – ident: e_1_3_4_65_2 doi: 10.1038/sj.ki.5001983 – ident: e_1_3_4_80_2 doi: 10.1152/ajpheart.00134.2002 – ident: e_1_3_4_15_2 doi: 10.2337/diacare.27.3.765 – ident: e_1_3_4_74_2 doi: 10.1161/circresaha.107.158915 – ident: e_1_3_4_47_2 doi: 10.1172/JCI200314172 – ident: e_1_3_4_50_2 doi: 10.1093/cvr/cvq366 – ident: e_1_3_4_21_2 doi: 10.1152/ajpheart.00998.2007 – ident: e_1_3_4_4_2 doi: 10.1016/0006-291X(87)90929-6 – ident: e_1_3_4_32_2 doi: 10.1042/CS20050307 – ident: e_1_3_4_75_2 doi: 10.1161/atvbaha.110.222638 – ident: e_1_3_4_78_2 doi: 10.1161/01.HYP.38.3.655 – ident: e_1_3_4_26_2 doi: 10.1124/pr.108.000240 – ident: e_1_3_4_8_2 doi: 10.1016/S0091-679X(08)60010-2 – ident: e_1_3_4_52_2 doi: 10.1016/j.freeradbiomed.2008.08.013 – ident: e_1_3_4_3_2 doi: 10.1016/0003-9861(87)90060-9 – ident: e_1_3_4_40_2 doi: 10.1161/01.cir.0000093661.90582.c4 – ident: e_1_3_4_46_2 doi: 10.1016/j.jacc.2008.04.019 – ident: e_1_3_4_19_2 doi: 10.1002/cbic.200500527 – ident: e_1_3_4_29_2 doi: 10.1172/JCI118623 – ident: e_1_3_4_82_2 doi: 10.1056/NEJMoa013591 – ident: e_1_3_4_9_2 doi: 10.1038/ncpneph0143 – ident: e_1_3_4_10_2 doi: 10.1006/niox.1996.0106 – ident: e_1_3_4_44_2 doi: 10.1161/01.hyp.0000156746.25300.1c – ident: e_1_3_4_7_2 doi: 10.1161/01.atv.0000128897.54893.26 – ident: e_1_3_4_33_2 doi: 10.1152/ajprenal.00423.2003 – ident: e_1_3_4_90_2 doi: 10.1016/j.freeradbiomed.2007.06.019 – ident: e_1_3_4_43_2 doi: 10.1152/ajpheart.1986.250.5.H822 – ident: e_1_3_4_63_2 doi: 10.2337/db06-1772 – ident: e_1_3_4_60_2 doi: 10.1161/circresaha.107.156901 – ident: e_1_3_4_28_2 doi: 10.1161/01.RES.80.1.45 – ident: e_1_3_4_54_2 doi: 10.1097/01.ASN.0000090747.59919.D2 – ident: e_1_3_4_41_2 doi: 10.1007/s11906-011-0187-x – ident: e_1_3_4_72_2 doi: 10.1093/ndt/17.11.1999 – ident: e_1_3_4_6_2 doi: 10.1097/00005344-199204002-00018 – ident: e_1_3_4_88_2 doi: 10.1248/bpb.28.641 – ident: e_1_3_4_30_2 doi: 10.1016/S0165-6147(03)00233-5 – ident: e_1_3_4_45_2 doi: 10.1172/JCI118935 – ident: e_1_3_4_16_2 doi: 10.1161/01.CIR.98.18.1842 – ident: e_1_3_4_37_2 doi: 10.1016/j.freeradbiomed.2011.06.011 – ident: e_1_3_4_69_2 doi: 10.1111/j.1523-1755.2005.00392.x – ident: e_1_3_4_67_2 doi: 10.1152/ajpheart.01103.2007 – ident: e_1_3_4_59_2 doi: 10.1159/000103284 – ident: e_1_3_4_35_2 doi: 10.1053/j.ajkd.2007.09.020 – ident: e_1_3_4_39_2 doi: 10.1161/ATVBAHA.108.181610 – ident: e_1_3_4_76_2 doi: 10.1074/jbc.M109.037036 – ident: e_1_3_4_11_2 doi: 10.1046/j.1365-2362.2003.01150.x – ident: e_1_3_4_24_2 doi: 10.1161/01.hyp.0000259669.40991.1e – ident: e_1_3_4_51_2 doi: 10.1089/ars.2006.8.1597 – ident: e_1_3_4_70_2 doi: 10.1161/hypertensionaha.110.157115 – ident: e_1_3_4_56_2 doi: 10.1016/j.freeradbiomed.2009.07.006 – ident: e_1_3_4_20_2 doi: 10.1016/j.phrs.2009.08.002 – ident: e_1_3_4_64_2 doi: 10.1016/S0895-7061(02)02278-1 – ident: e_1_3_4_2_2 doi: 10.1016/S0021-9258(18)62716-4 – ident: e_1_3_4_83_2 doi: 10.1161/hypertensionaha.109.135426 – ident: e_1_3_4_48_2 doi: 10.1161/01.RES.87.2.99 – ident: e_1_3_4_12_2 doi: 10.1046/j.1523-1755.2002.00437.x – ident: e_1_3_4_42_2 doi: 10.1038/hr.2010.201 – ident: e_1_3_4_13_2 doi: 10.1016/S0140-6736(01)07217-8 – ident: e_1_3_4_22_2 doi: 10.1161/01.res.0000129578.76799.75 – ident: e_1_3_4_53_2 doi: 10.1161/01.hyp.0000200023.02195.73 – ident: e_1_3_4_57_2 doi: 10.1038/sj.ki.5000067 – ident: e_1_3_4_68_2 doi: 10.1152/ajpheart.00626.2004 – ident: e_1_3_4_73_2 doi: 10.1093/ndt/gfg452 – ident: e_1_3_4_89_2 doi: 10.1111/j.1476-5381.2009.00259.x – ident: e_1_3_4_55_2 doi: 10.1161/hypertensionaha.110.152959 – ident: e_1_3_4_81_2 doi: 10.1007/s10157-008-0034-9 – ident: e_1_3_4_34_2 doi: 10.1161/01.RES.0000020404.01971.2F – ident: e_1_3_4_79_2 doi: 10.1161/01.hyp.0000158262.11935.d0 – ident: e_1_3_4_31_2 doi: 10.1161/01.hyp.0000154365.30593.d3 – ident: e_1_3_4_61_2 doi: 10.1111/j.1523-1755.2000.00380.x – ident: e_1_3_4_84_2 doi: 10.1161/01.hyp.0000052945.84627.8f – ident: e_1_3_4_36_2 doi: 10.1152/ajpregu.90506.2008 – ident: e_1_3_4_5_2 doi: 10.1016/S0021-9258(18)81786-0 – ident: e_1_3_4_77_2 doi: 10.1016/j.bbrc.2004.01.120 – ident: e_1_3_4_14_2 doi: 10.1038/sj.ki.5000417 – ident: e_1_3_4_38_2 doi: 10.1161/hypertensionaha.109.142422 – ident: e_1_3_4_66_2 doi: 10.1152/ajpregu.90875.2008 – ident: e_1_3_4_25_2 doi: 10.1152/ajpregu.00250.2005 |
SSID | ssj0014447 |
Score | 2.3380466 |
SecondaryResourceType | review_article |
Snippet | Plasma levels of asymmetric dimethylarginine or markers of reactive oxygen species are increased in subjects with risk factors for cardiovascular disease or... |
SourceID | proquest pubmed pascalfrancis crossref wolterskluwer |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 375 |
SubjectTerms | Animals Arginine - analogs & derivatives Arginine - metabolism Arterial hypertension. Arterial hypotension Biological and medical sciences Blood and lymphatic vessels Cardiology. Vascular system Cardiovascular Diseases - epidemiology Cardiovascular Diseases - metabolism Cardiovascular Diseases - physiopathology Disease Models, Animal Endothelium, Vascular - physiopathology Experimental diseases Humans Kidney Diseases - epidemiology Kidney Diseases - metabolism Kidney Diseases - physiopathology Medical sciences Rats Reactive Oxygen Species - metabolism Risk Factors |
Title | Asymmetric Dimethylarginine and Reactive Oxygen Species: Unwelcome Twin Visitors to the Cardiovascular and Kidney Disease Tables |
URI | https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00004268-201202001-00003 https://www.ncbi.nlm.nih.gov/pubmed/22215715 https://www.proquest.com/docview/918035994 |
Volume | 59 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELbKkBASQvwc5cfkB96qlCaxk5i3qhsqjG0gtVCeosSxUUSXTmurrjzxF_A3cxe7bVKKGLxEVVQ7Se_r-b7L5ztCXko3jJIwDRwIJUKHuQl3koQxh2dpojwWdnRZnf_kNOgP2bsRHzUaPyuqpfksbcvvO_eV_I9V4RzYFXfJ_oNl15PCCfgM9oUjWBiO17Jxd7o8P8eWWBJcF_aCXgJP_YotH5TdeJiU7qx1drWESUyzeSOCGxYLNYZ7Uq3BIi9an_JpXvbdsaFory5TxcmO86wAB3Jo3ui0BrjnalqNbftAaS9LQXyJqOgQc_RGhaSu2i1XhKKSd_j89n3vbLRV38AmYm0WAuUcNUXHrmoSZRYiH6PUp5rAFAwd7KjqgW1N8LxChI079U1XFbsy-6a5y-9OP0Cn3__y4QgowCmuQd1-F9eCthuFvlXN1iptb62Aa10ismUfKOMNctMD2oF-8_jj5q0UY8xuvzfPYIvYwvVf_fnqtYDnzgUYLhlr0zRlF6uB7ywmKJSYfiv3SVSincE9ctfSFNo1mLtPGqp4QG6dWCHGQ_JjAz26DT0KaKEr6FEDPWqh95qugUcReHQFPDqbUAAerQOvnMoAj1rgUQO8R2T45mjQ6zu2mYcjfYH9AjMtPZEwDwm4ZlnWiTT4f8611FpGvKOYl0mZ8iQNIq0Drj0R8DTTgkdBoKT_mOwVk0I9IVSFYeprpoWWnGUyTSNg3VJkUcZlwl3dJGL1i8fSVrrHhivjuGS8gRtvWQtpcGys1ST-euyFqfdyrVEHNcOuh64A1SR0ZekY_De-lEsKNZlPY-FGWEVTsCbZNwjYDPYgHg9dGOzUIBGbLdJxye-9AH2i63WMOBJzHE__djfPyO3Nf_g52ZtdztULiK1n6UEJ-F_6WM6l |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Asymmetric+Dimethylarginine+and+Reactive+Oxygen+Species%3A+Unwelcome+Twin+Visitors+to+the+Cardiovascular+and+Kidney+Disease+Tables&rft.jtitle=Hypertension+%28Dallas%2C+Tex.+1979%29&rft.au=WILCOX%2C+Christopher+S&rft.date=2012-02-01&rft.pub=Lippincott+Williams+%26+Wilkins&rft.issn=0194-911X&rft.volume=59&rft.issue=2&rft.spage=375&rft.epage=381&rft_id=info:doi/10.1161%2FHYPERTENSIONAHA.111.187310&rft.externalDBID=n%2Fa&rft.externalDocID=25493495 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0194-911X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0194-911X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0194-911X&client=summon |